Time filter

Source Type

Yamauchi M.,Hiroshima Prefectural Hospital | Shinozaki K.,Hiroshima Prefectural Hospital | Hatanaka N.,HOG GC Hiroshima Oncology Group of Gastric Cancer | Yamamoto M.,HOG GC Hiroshima Oncology Group of Gastric Cancer | And 4 more authors.
Japanese Journal of Cancer and Chemotherapy | Year: 2011

Aim: The Hiroshima Oncology Group of Gastric Cancer (HOG-GC) distributed a multiple-answer questionnaire to investigate the realities of chemotherapy for gastric cancer. Subjects and Method: Seventy-six hospitals in Hiroshima were surveyed. The Japanese classification was used for the staging criteria. Results: Forty-one hospitals, including 10 centers for cancer treatment, completed and returned the questionnaires. For stage II & III cases requiring adjuvant chemotherapy, S-1 was the most commonly used (84%) regimen. A standard starting dose was used in 79% of these cases, and S-1 was administered for one year continuously in 84% of the cases. For stage I B & II (T1), S-1 and UFT were used in 45% and 20% of the cases, respectively. In cases with non-resectable gastric cancer, S-1 plus CDDP and S-1 alone were used as a first-line therapy in 62% and 26% of the patients under 75 years age, respectively, and in 33% and 46% of the patients older than 75 years of age, respectively. In patients with ascites and peritoneal dissemination, S-1 plus CDDP, S-1, S-1 plus DTX, S-1 plus PTX, and PTX were used in 26%, 15%, 21%, 17%, and 17% of cases, respectively. Some of the patients with peritoneal dissemination underwent gastrectomy. Conclusion: S-1 was widely used for gastric cancer chemotherapy in Hiroshima Prefecture. Taxane-containing regimens or palliative gastrectomy were commonly used in cases with peritoneal dissemination.

Loading HOG GC Hiroshima Oncology Group of Gastric Cancer collaborators
Loading HOG GC Hiroshima Oncology Group of Gastric Cancer collaborators